Phaseline

Companies › H. Lundbeck

H. Lundbeck: clinical trials, targets and expected readouts

6 active drug programs in 13 registered trials: 5 Phase 3, 5 Phase 1, 3 Phase 2; Neurology, Other, Genitourinary, Metabolic and endocrine; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Eptinezumab
Calcitonin gene-related peptide inhibitor
CALCA, CALCBPhase 3Chronic Migraine in Children; Episodic Migraine; Migraine; Post Traumatic HeadacheMar 2027
Amlenetug (Lu AF82422)–Phase 3Multiple System AtrophyFeb 2028
Lu AF28996–Phase 2Parkinson's Disease; Parkinson DiseaseMay 2027
Lu AG13909
11β-hydroxylase inhibitor
CYP11B1Phase 2Cushing's Disease; Congenital Adrenal HyperplasiaAug 2027
Lu AH69593–Phase 1Healthy Participants; NarcolepsyNov 2026
Lu AG22515
Unclear - no mechanism stated for this investigational compound
–Phase 1Thyroid Eye Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06557850Lu AG22515Phase 1Thyroid Eye DiseaseOphthalmologyMar 2026
NCT07775261Lu AH69593Phase 1Healthy ParticipantsOtherNov 2026
NCT07613710Lu AH69593Phase 1NarcolepsyNeurologyFeb 2027
NCT04965675EptinezumabPhase 3Chronic Migraine in ChildrenNeurologyMar 2027
NCT07513441Lu AF28996Phase 1Parkinson DiseaseNeurologyMay 2027
NCT07191145EptinezumabPhase 3Post Traumatic HeadacheNeurologyJun 2027
NCT05897320EptinezumabPhase 3Episodic MigraineNeurologyJul 2027
NCT06471829Lu AG13909Phase 2Cushing's DiseaseMetabolic and endocrineAug 2027
NCT05669950Lu AG13909Phase 1Congenital Adrenal HyperplasiaGenitourinaryDec 2027
NCT06706622Amlenetug (Lu AF82422)Phase 3Multiple System AtrophyNeurologyFeb 2028
NCT05104476Amlenetug (Lu AF82422)Phase 2Multiple System AtrophyNeurologyMar 2028
NCT05164172EptinezumabPhase 3MigraineNeurologyApr 2028
NCT07514858Lu AF28996Phase 2Parkinson's DiseaseNeurologyOct 2028

Targets

CALCA (1) CALCB (1) CYP11B1 (1)

Companies with the same targets

Eli Lilly Actinogen Medical RECORDATI GROUP

Companies built like this

Centessa Pharmaceuticals (UK) Actinogen Medical Beijing Suncadia Pharmaceuticals UCB Biopharma SRL Praxis Precision Medicines

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.